首页> 外文期刊>Traffic Injury Prevention >Gender Differences in Highway Driving Performance After Administration of Sleep Medication: A Review of the Literature
【24h】

Gender Differences in Highway Driving Performance After Administration of Sleep Medication: A Review of the Literature

机译:睡眠药物给药后公路驾驶性能的性别差异:文献综述

获取原文
获取原文并翻译 | 示例
       

摘要

Objectives: It is generally assumed that there are minimal gender differences in the safety and efficacy of central nervous system drugs, as is evidenced by men and women receiving the same drug dosage. There is, however, evidence that drugs may have a differential effect on performance in men and women, given reported differences in pharmacokinetics as well as the presence or absence and severity of adverse effects. It is especially important to verify whether gender differences in performance exist in case of activities that have potentially dangerous outcomes such as driving a car. This review summarizes the current scientific evidence on gender differences in driving performance after treatment with hypnotic drugs. Methods: A literature search was conducted to obtain all studies that conducted on-road driving tests to examine the effects hypnotic drugs on driving. Cross-references were checked and technical reports and raw data were obtained, if possible. Results: Fourteen studies were evaluated. Many studies did not allow analyses of gender effects because only women were included. Others did not report data on gender analyses. Technical reports and additional data analyses revealed significant gender differences in driving performance the morning following bedtime administration of flurazepam (30 mg) and after middle-of-the-night administration of zolpidem (10 mg). No significant gender differences were found for ramelteon (8 mg), lormetazepam (1 and 2 mg), zaleplon (10 and 20 mg), and zopiclone (7.5 mg). Conclusions: Although the available data are limited, the results show that significant gender differences have been found for some drugs but not others. Therefore, in the future more research is needed to reveal potential gender differences and to determine what mediates them.
机译:目标:一般认为,中枢神经系统药物在安全性和有效性方面的性别差异最小,这是由接受相同药物剂量的男性和女性所证明的。然而,有证据表明,鉴于已报道的药代动力学差异以及不良反应的存在与否以及严重程度,药物对男性和女性的表现可能有不同的影响。验证在驾驶等潜在危险结果的活动中,是否存在性别差异,这一点尤为重要。这篇综述总结了有关催眠药治疗后驾驶表现中性别差异的最新科学证据。方法:进行文献检索以获得所有进行道路驾驶测试的研究,以检查催眠药对驾驶的影响。如果可能,检查交叉引用并获得技术报告和原始数据。结果:评估了十四项研究。许多研究不允许分析性别影响,因为只包括妇女。其他人没有报告性别分析数据。技术报告和其他数据分析显示,在睡前服用氟硝西m(30毫克)后和半夜服用唑吡坦(10毫克)后的早晨,驾驶性能存在明显的性别差异。拉美替尼(8 mg),洛美他西(1和2 mg),扎来普隆(10和20 mg)和佐匹克隆(7.5 mg)没有发现明显的性别差异。结论:尽管可用数据有限,但结果表明,某些药物发现了明显的性别差异,而其他药物则没有。因此,将来需要进行更多的研究以揭示潜在的性别差异并确定调解它们的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号